Exhaled nitric oxide helps discriminating asthmatic children with and without positive specific IgE to aeroallergens

Li-Ching Fang1, Shyh-Dar Shyur1,2, Jen-Yu Wang3

  • 1Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan.

Insights

Fractional exhaled nitric oxide (FeNO) levels are higher in sensitized asthmatic children. Age-specific FeNO cut-off values can distinguish between children with and without aeroallergen sensitization.

Area of Science:

  • Pediatric Allergy and Immunology
  • Respiratory Medicine
  • Clinical Diagnostics

Background:

  • Aeroallergen sensitization is linked to elevated fractional exhaled nitric oxide (FeNO) levels.
  • Understanding FeNO's role in allergic respiratory diseases is crucial for diagnosis and management.

Purpose of the Study:

  • To determine age-specific fractional exhaled nitric oxide (FeNO) cut-off values for differentiating aeroallergen sensitization in asthmatic children.
  • To evaluate the predictive performance of these FeNO cut-offs in children with allergic rhinitis (AR).

Main Methods:

  • A study involving 564 asthmatic children (5-18 years) with allergic rhinitis (AR).
  • Patients were categorized into sensitized (positive specific immunoglobulin E [IgE] to common aeroallergens) and non-sensitized groups.
  • Pulmonary function, FeNO, eosinophil counts, and IgE levels were analyzed across age groups: preschool, elementary, and adolescent.

Main Results:

  • Preschoolers: FeNO ≥15.5 ppb (AUC 0.72) differentiated sensitization.
  • Elementary students: FeNO ≥19.5 ppb (AUC 0.81) showed optimal discrimination.
  • Adolescents: FeNO ≥27.5 ppb (AUC 0.76) was identified as the key cut-off for sensitization.

Conclusions:

  • Aeroallergen sensitization significantly elevates FeNO levels in asthmatic children.
  • Age-specific FeNO cut-off values are essential for accurately identifying sensitization in pediatric asthma.
  • These findings support FeNO as a valuable biomarker in managing pediatric allergic respiratory conditions.
Abstract

Related Concept Videos

Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.6K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.2K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.9K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.9K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.4K